Global Viral and Non-Viral Vector Manufacturing Market Size is valued at USD 8.0 Billion in 2024 and is predicted to reach USD 56.8 Billion by the year 2034 at a 21.9% CAGR during the forecast period for 2025-2034.
Viral vectors are genetically modified viruses utilised as carriers for introducing exogenous genetic material into cells through their viral genome. In contrast, nonviral vectors encompass a range of chemical vectors, including inorganic particles, lipid-based vectors, polymer-based vectors, and peptide-based vectors, which also serve as vehicles for delivering foreign genetic material into cells.
Viral vectors are used to convey genetic material into cells and have become a popular method for gene transfer due to their high transfection effectiveness, sustained gene expression, and efficient gene delivery. Plasmid DNA is essential in the healthcare industry, as it is used as a therapeutic agent in gene therapy and the production of vaccine antigens.
The growing usage of gene therapy to treat viral infections such as adeno-associated viruses, poxviruses, herpes simplex viruses, and retroviruses is expected to boost gene therapy acceptance, which will help to push viral vector and plasmid DNA manufacturing market expansion. Furthermore, demand for viral vectors and plasmid DNA production is expected to rise in the next years due to the rising need for DNA treatments and cancer research R&D. The partnership focused on increasing the chromatographic separation of AAV-based vectors using several AAV types. As a result, such collaborations are expected to improve the manufacturing efficiency and scalability of gene therapies, allowing for the global availability of viral vectors and creating lucrative market opportunities. Gene treatments are being developed via viral vectors and plasmid DNA, which is one of the fastest expanding areas in advanced medicines.
Healthcare companies are developing DNA vectors for vaccine manufacturing. Many challenges affect the manufacturers of viral vectors and plasmid DNA whose products are in phase III clinical trials and commercial production of viral vectors. Many existing vector production technologies are inadequate in terms of productivity, efficiency, stability, and other factors.
The Viral and Non-Viral Vector Manufacturing market is segmented based on vector type, diseases, and application. Based on vector type, the market is segmented as Viral Vector (Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, Other Viral Vector), Non-Viral Vectors, (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Other Non-Viral Vector (Peptide-Based and Hybrid/Combination)). Based on application, the market is categorized into gene therapy, vaccinology, cell therapy and other applications. The market is segmented based on diseases includes Cancer, Genetic Disorder, and Infectious diseases.
The Non-Viral vectors category is expected to hold a significant share in the global Viral and Non-Viral Vector Manufacturing market in 2021. The COVID-19 viral vector vaccines use non-replicating viral vectors. The market will continue to increase as more non-viral vectors are used in vaccine development in the occurrence of a pandemic. According to a PubMed paper published in 2017, the development of non-viral DNA vectors has progressed substantially, particularly in the reduction of plasmid vector length. This factor is also playing a vital role in the segment's growth.
The vaccinology segment is projected to proliferate in the global Viral and Non-Viral Vector Manufacturing market. This is because viral vectors are regularly used in vaccine development due to their efficiency benefits. Positives include the ability to encourage a comprehensive immunological response, as well as the safety profiles and convenience of manufacture. Furthermore, the European Medicines Agency (EMA) has approved the use of AAV in clinical trials since it may express epitomal genes without integrating into the host genome. In addition, attempts to design and enhance immunization schedules will drive the development of novel vaccines, especially in countries such as the US, Germany, the UK, China, and India.
The North America Viral and Non-Viral Vector Manufacturing market is expected to register the highest market share in terms of revenue soon due to the presence of a significant number of research centres engaged in advanced therapy research and development. Furthermore, the construction of manufacturing units by competitors from other countries in North America is a driving force behind the region's market expansion. In addition, Asia Pacific is projected to grow at a rapid rate in the global Viral and Non-Viral Vector Manufacturing market. This is due to the creation of accelerated approval processes, the growing pool of patient population, growing private and government investments, and rising healthcare requirements. Furthermore, the unmet demands in the field of personalized medicine are driving the growing demand for viral vectors.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 8.0 Billion |
| Revenue Forecast In 2034 | USD 56.8 Billion |
| Growth Rate CAGR | CAGR of 21.9% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Vector type, By Disease, By Application |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Boehringer Ingelheim, Catalent, Inc., FUJIFILM Holdings Corporation, Danaher Corporation, Rescript Biotech Corporation, Lonza Group AG, Merck Kagan Inc., Oxford Biomedical plc, Sartorius AG, Takara Bio Inc, Thermo Fisher Scientific Inc, Wuxi Optec, Acuities Therapeutic, Evonik Industries AG, Exiled, Inc., Entos Pharmaceuticals, Genevant Sciences GmbH, T&T Scientific Corporation, Moderna, Inc and CureVac N.V. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
By Vector Type
By Disease
By Application
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.